Report
Guy Sips

Amoéba Brazil: an attractive growth market for biocontrol – AXPERA shows promise

Amoéba has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world's leading producer.
We maintain our Buy and € 1.4 Target Price.
Underlying
Amoeba SA

Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Guy Sips

ResearchPool Subscriptions

Get the most out of your insights

Get in touch